Variations in pharmacology of β-blockers may contribute to heterogeneous results in trials of perioperative β-blockade

Anesthesiology

Volumn 113, Issue 3, 2010, Pages 585-592

  Badgett, Robert G ^a,b,c   Lawrence, Valerie A ^a,b,c   Cohn, Steven L ^a,b,d  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CYTOCHROME P450; CYTOCHROME P450 2D6;

ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BRADYCARDIA; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; GENETIC POLYMORPHISM; HUMAN; META ANALYSIS; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; SYSTEMATIC REVIEW; COMPARATIVE STUDY; GENETIC VARIABILITY; GENETICS; METABOLISM; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC BETA-ANTAGONISTS; CYTOCHROME P-450 CYP2D6; GENETIC VARIATION; HUMANS; PERIOPERATIVE CARE; POLYMORPHISM, GENETIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77957002544     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e3181e73eea     Document Type: Article

References (44)

1. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine, Society for Vascular Surgery, Fleischmann KE, Beckman JA, Buller CE, Calkins H, Fleisher LA, Freeman WK, Froehlich JB, Kasper EK, Kersten JR, Robb JF, Valentine RJ: 2009 ACCF/AHA focused update on perioperative beta blockade. J Am Coll Cardiol 2009; 54:2102-2128
2. Bangalore S, Wetterslev J, Pranesh S, Sawhney S, Gluud C, Messerli FH: Perioperative beta blockers in patients having non-cardiac surgery: A meta-analysis. Lancet 2008; 372: 1962-1976
3. Poldermans D, Schouten O, van Lier F, Hoeks SE, van de Ven L, Stolker RJ, Fleisher LA: Perioperative strokes and β-blockade. ANESTHESIOLOGY 2009; 111:940-945
4. Zaugg M, Bestmann L, Wacker J, Lucchinetti E, Boltres A, Schulz C, Hersberger M, Kälin G, Furrer L, Hofer C, Blumenthal S, Müller A, Zollinger A, Spahn DR, Borgeat A: Adrenergic receptor genotype but not perioperative bisoprolol therapy may determine cardiovascular outcome in at-risk patients undergoing surgery with spinal block: The Swiss Beta Blocker in Spinal Anesthesia (BBSA) study: A double-blinded, placebo-controlled, multicenter trial with 1-year follow-up. ANESTHESIOLOGY 2007; 107:33-44
5. Lanfear DE, Spertus JA, McLeod HL: Beta2-adrenergic receptor genotype predicts survival: Implications and future directions. J Cardiovasc Nurs 2006; 21:474-477
6. Shin J, Johnson JA: Pharmacogenetics of beta-blockers. Pharmacotherapy 2007; 27:874-887
7. Wolf CR, Smith G: Pharmacogenetics. Br Med Bull 1999; 55:366-386
8. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W: Potential role of pharmacogenomics in reducing adverse drug reactions: A systematic review. JAMA 2001; 286:2270-2279
9. Fux R, Mörike K, Pröhmer AM, Delabar U, Schwab M, Schaeffeler E, Lorenz G, Gleiter CH, Eichelbaum M, Kivistö KT: Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: A prospective clinical study. Clin Pharmacol Ther 2005; 78:378-387
10. Baker JG: The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol 2005; 144:317-322
11. Beattie WS, Wijeysundera DN, Karkouti K, McCluskey S, Tait G: Does tight heart rate control improve beta-blocker efficacy? An updated analysis of the noncardiac surgical randomized trials. Anesth Analg 2008; 106:1039-1048
12. Mangano DT, Wong MG, London MJ, Tubau JF, Rapp JA: Perioperative myocardial ischemia in patients undergoing noncardiac surgery-II: Incidence and severity during the 1st week after surgery. The Study of Perioperative Ischemia (SPI) Research Group. J Am Coll Cardiol 1991; 17: 851-857
13. Ragoonanan TE, Beattie WS, Mazer CD, Tsui AK, Leong-Poi H, Wilson DF, Tait G, Yu J, Liu E, Noronha M, Dattani ND, Mitsakakis N, Hare GM: Metoprolol reduces cerebral tissue oxygen tension after acute hemodilution in rats. ANESTHESIOLOGY 2009; 111:988-1000
14. Beattie WS, Wijeysundera DN, Karkouti K, McCluskey S, Tait G, Mitsakakis N, Hare GM: Acute surgical anemia influences the cardioprotective effects of β-blockade: A single-center, propensity-matched cohort study. ANESTHESIOLOGY 2010; 112:25-33
15. Kaplan NM, Lieberman E: Treatment of hypertension: Drug therapy, Clinical Hypertension, 6th edition. Edited by Kaplan NM. Baltimore, Williams & Wilkins, 1994, pp 191-280
16. Mangano DT, Layug EL, Wallace A, Tateo I: Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med 1996; 335:1713-1720
17. Neary WD, McCrirrick A, Foy C, Heather BP, Earnshaw JJ: Lessons learned from a randomised controlled study of perioperative beta blockade in high risk patients undergoing emergency surgery. Surgeon 2006; 4:139-143
18. Packer M, Lee WH, Yushak M, Medina N: Comparison of captopril and enalapril in patients with severe chronic heart failure. N Engl J Med 1986; 315:847-853 (Pubitemid 16028479)
19. Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof E, Fleischmann KE, Freeman WK, Froehlich JB, Kasper EK, Kersten JR, Riegel B, Robb JF, ACC/AHA TASK FORCE MEMBERS, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Buller CE, Creager MA, Ettinger SM, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Lytle BW, Ornato JP, Page RL, Riegel B, Tarkington LG, Yancy CW: ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation 2007; 116:1971-1996
20. Poldermans D, Bax JJ, Boersma E, De Hert S, Eeckhout E, Fowkes G, Gorenek B, Hennerici MG, Iung B, Kelm M, Kjeldsen KP, Kristensen SD, Lopez-Sendon J, Pelosi P, Philippe F, Pierard L, Ponikowski P, Schmid JP, Sellevold OF, Sicari R, Van den Berghe G, Vermassen F, Hoeks SE, Vanhorebeek I, Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery, European Society of Cardiology, European Society of Anaesthesiology: Guidelines for preoperative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA). Eur Heart J 2009; 2769-2812
21. Brady AR, Gibbs JS, Greenhalgh RM, Powell JT, Sydes MR, POBBLE trial investigators: Perioperative beta-blockade (POBBLE) for patients undergoing infrarenal vascular surgery: Results of a randomized double-blind controlled trial. J Vasc Surg 2005; 41:602-609
22. Yang H, Raymer K, Butler R, Parlow J, Roberts R: The effects of perioperative beta-blockade: Results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial. Am Heart J 2006; 152:983-990
23. Mangano DT, Browner WS, Hollenberg M, London MJ, Tubau JF, Tateo IM: Association of perioperative myocardial ischemia with cardiac morbidity and mortality in men undergoing noncardiac surgery. The Study of Perioperative Ischemia Research Group. N Engl J Med 1990; 323: 1781-1788
24. Poldermans D, Boersma E, Bax JJ, Thomson IR, van de Ven LL, Blankensteijn JD, Baars HF, Yo TI, Trocino G, Vigna C, Roelandt JR, van Urk H: The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med 1999; 341:1789-1794
25. Dunkelgrun M, Boersma E, Schouten O, Koopman-van Gemert AW, van Poorten F, Bax JJ, Thomson IR, Poldermans D, Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group: Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediaterisk patients undergoing noncardiovascular surgery: A randomized controlled trial (DECREASE-IV). Ann Surg 2009; 249:921-926
26. Juul AB, Wetterslev J, Gluud C, Kofoed-Enevoldsen A, Jensen G, Callesen T, Nørgaard P, Fruergaard K, Bestle M, Vedelsdal R, Miran A, Jacobsen J, Roed J, Mortensen MB, Jørgensen L, Jørgensen J, Rovsing ML, Petersen PL, Pott F, Haas M, Albret R, Nielsen LL, Johansson G, Stjernholm P, Mølgaard Y, Foss NB, Elkjaer J, Dehlie B, Boysen K, Zaric D, Munksgaard A, Madsen JB, øberg B, Khanykin B, Blemmer T, Yndgaard S, Perko G, Wang LP, Winkel P, Hilden J, Jensen P, Salas N, DIPOM Trial Group: Effect of perioperative beta blockade in patients with diabetes undergoing major non-cardiac surgery: Randomised placebo controlled, blinded multicentre trial. BMJ 2006; 332:1482
27. POISE Study Group, Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, Villar JC, Xavier D, Chrolavicius S, Greenspan L, Pogue J, Pais P, Liu L, Xu S, Málaga G, Avezum A, Chan M, Montori VM, Jacka M, Choi P: Effects of extendedrelease metoprolol succinate in patients undergoing noncardiac surgery (POISE trial): A randomised controlled trial. Lancet 2008; 371:1839 - 1847
28. Deeks JJ, Higgins JPT, Altman DG, Cochrane Statistical Methods Group: 9.5.2 Identifying and measuring heterogeneity, Cochrane Handbook for Systematic Reviews of Interventions, 5.0.2 (updated September 2009) edition. Edited by Higgins JPT and Green S. Copenhagen, Denmark, The Cochrane Collaboration, 2009
29. Higgins JPT, Green S: Cochrane Handbook for Systematic Reviews of Interventions, 5.0.2 (updated September 2009) edition. Copenhagen, Denmark, The Cochrane Collaboration, 2009
30. Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, Xie JX, Liu LS, COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group: Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: Randomised placebo-controlled trial. Lancet 2005; 366:1622-1632
31. Anonymous: Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 1986; 2:57-66
32. Redelmeier D, Scales D, Kopp A: Beta blockers for elective surgery in elderly patients: Population based, retrospective cohort study. BMJ 2005; 331:932
33. Chan AW, Altman DG: Identifying outcome reporting bias in randomised trials on PubMed: Review of publications and survey of authors. BMJ 2005; 330:753
34. Byington RP, Curb JD, Mattson ME: Assessment of doubleblindness at the conclusion of the beta-Blocker Heart Attack Trial. JAMA 1985; 253:1733-1736
35. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, Gluud C, Martin RM, Wood AJ, Sterne JA: Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: Metaepidemiological study. BMJ 2008; 336:601-605
36. Goodman SN: Stopping at nothing? Some dilemmas of data monitoring in clinical trials. Ann Intern Med 2007; 146: 882-887
37. Wuttke H, Rau T, Heide R, Bergmann K, Böhm M, Weil J, Werner D, Eschenhagen T: Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 2002; 72:429-437
38. Terra SG, Pauly DF, Lee CR, Patterson JH, Adams KF, Schofield RS, Belgado BS, Hamilton KK, Aranda JM, Hill JA, Yarandi HN, Walker JR, Phillips MS, Gelfand CA, Johnson JA: Beta-adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/ extended release in heart failure. Clin Pharmacol Ther 2005; 77:127-137
39. Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly DF, Eberst K, Leeder JS, Phillips MS, Gelfand CA, Johnson JA: Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther 2004; 76:536-544
40. Neutel JM, Schnaper H, Cheung DG, Graettinger WF, Weber MA: Antihypertensive effects of beta-blockers administered once daily: 24-hour measurements. Am Heart J 1990; 120:166-171
41. Sarafidis P, Bogojevic Z, Basta E, Kirstner E, Bakris GL: Comparative efficacy of two different beta-blockers on 24-hour blood pressure control. J Clin Hypertens (Greenwich) 2008; 10:112-118
42. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS: Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-944
43. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg PG, Ferrières J, Danchin N, Becquemont L, French Registry of Acute ST-Elevation and Non- ST-Elevation Myocardial Infarction (FAST-MI) Investigators: Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360:363-375
44. Diamond GA, Kaul S: Bayesian classification of clinical practice guidelines. Arch Intern Med 2009; 169:1431-1435